This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Omeros Corporation Files Universal Shelf Registration Statement To Replace Expiring Universal Shelf Registration Statement

SEATTLE, Oct. 17, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has filed a replacement universal shelf registration statement (the "2013 Registration Statement") with the Securities and Exchange Commission (the "SEC"). The 2013 Registration Statement was filed as routine course of business due to the impending expiration of the company's existing universal shelf registration statement (the "2010 Registration Statement") that, under SEC rules, would have expired on Friday, October 18, 2013. Pursuant to SEC rules, the expiration date of the 2010 Registration Statement has been extended until the earlier of the effective date of the 2013 Registration Statement or April 16, 2014. Upon effectiveness, the company may use the 2013 Registration Statement to offer and sell common and preferred stock, debt securities and other securities having an aggregate offering amount of no more than $100 million, which is the amount that was registered under the 2010 Registration Statement. The 2013 Registration Statement, once it becomes effective, will continue to provide the company with flexibility to access the public capital markets in response to financing and business opportunities that may arise from time to time over its expected three-year term. No sales will occur under the 2013 Registration Statement prior to the time it becomes effective.

This press release is neither an offer to sell nor the solicitation of an offer to buy any securities and shall not constitute an offer or solicitation in any jurisdiction where such offer or solicitation is unlawful.

About Omeros CorporationOmeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system.

Contact: Jennifer Cook WilliamsCook Williams Communications, Inc.Investor and Media Relations360.668.3701 jennifer@cwcomm.org

SOURCE Omeros Corporation

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs